HB 1469
In CommitteeHouse
ASAM 4 treatment criteria
Delaying the use of the ASAM 4 criteria, treatment criteria for addictive, substance related, and co-occurring conditions.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill delays the state’s adoption of the latest clinical guidelines for addiction treatment (ASAM Criteria, 4th edition) from January 1, 2026, to January 1, 2028, giving more time for planning and implementation. It also formalizes a joint review process between two state agencies before adopting future updates to these criteria.
- Delays the required use of the updated ASAM Criteria (4th edition) for addiction treatment from January 1, 2026, to January 1, 2028.
- Requires the Health Care Authority and Office of the Insurance Commissioner to jointly decide whether to adopt updated ASAM Criteria and set the implementation date for Medicaid managed care plans and private insurers.
- Mandates that both state agencies post their decision online to ensure transparency and public awareness.
- Applies to all versions of the ASAM Criteria—including those for adolescents and transition age youth—when they are updated by the American Society of Addiction Medicine.
Who is affected
- Individuals with substance use or co-occurring disorders — People receiving or seeking treatment for substance use disorders or co-occurring mental health conditions through Medicaid or private insurance plans covered by the state's behavioral health system.
- Health insurers and Medicaid managed care organizations — Health plans and insurance companies that cover addiction treatment services must follow updated clinical guidelines for determining treatment levels and coverage decisions.
- Behavioral health treatment providers — Behavioral health providers (e.g., counselors, clinics, hospitals) who use standardized criteria to assess patients and determine appropriate treatment levels; they must adjust practices to meet new standards.
- Washington State Health Care Authority and Office of the Insurance Commissioner — State agencies responsible for overseeing behavioral health policy and insurance regulation must coordinate to adopt and implement new clinical standards.
Pro/Con Analysis
Stronger case for concerns
Potential Benefits (2)
Provides additional time for behavioral health providers and insurers to prepare for system-wide changes, potentially reducing implementation errors, staff training gaps, and billing disruptions during the transition—benefiting operational continuity across the care ecosystem.
Business & EmploymentRef: Sec. 1 & Sec. 2 (delaying implementation to Jan. 1, 2028)Formalizes interagency coordination and transparency by requiring public posting of decisions, which may improve accountability and stakeholder trust, though it adds administrative burden to two state agencies.
Local GovernmentRef: Sec. 1 & Sec. 2 (joint review and public posting requirement)
Potential Concerns (3)
Delays adoption of evidence-based clinical standards for addiction treatment by two years, potentially prolonging inconsistent or substandard care for individuals with substance use disorders—particularly those on Medicaid—while newer criteria aim to improve assessment accuracy, match patients to appropriate levels of care, and reduce unnecessary institutionalization.
HealthcarePeopleRef: Sec. 1 & Sec. 2 (delaying ASAM 4 implementation to Jan. 1, 2028)Introduces an additional bureaucratic layer—requiring joint agency approval—before implementing future ASAM updates, which may slow or stall future improvements in treatment criteria, especially if agencies disagree or lack clear timelines, thereby delaying care enhancements for vulnerable populations.
HealthcarePeopleRef: Sec. 1 & Sec. 2 (mandating joint agency review before adoption of future updates)Postpones implementation of updated criteria specifically designed for adolescents and young adults—a high-risk group—potentially extending access barriers and misaligned care for youth seeking addiction treatment, who often need earlier, more developmentally appropriate interventions.
HealthcareLean peopleRef: Sec. 1 & Sec. 2 (delay applies to adolescent and transition-age youth versions)
Who Is Most Affected
Individuals with substance use or co-occurring disorders—especially low-income, Medicaid-enrolled, or youth—face longer delays in accessing standardized, evidence-based care. The delay may worsen outcomes for those in acute need, as inconsistent application of outdated criteria can lead to under- or over-treatment.
Behavioral health providers (e.g., community clinics, counselors) gain time to adjust workflows and train staff, but may face future uncertainty due to delayed standardization—potentially complicating billing, quality reporting, and inter-agency referrals.
Insurers and Medicaid managed care plans benefit from extended time to revise benefit design and prior authorization protocols, but may face future compliance costs if criteria changes are adopted later under tighter timelines.
The Health Care Authority and Office of the Insurance Commissioner gain formalized coordination authority, but also added administrative responsibility and potential political risk if decisions are perceived as delayed or inconsistent with clinical consensus.